{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:40:29Z","timestamp":1791409229540,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.eururo.2017.07.024","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T03:16:22Z","timestamp":1502766982000},"page":"828-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide"],"prefix":"10.1016","volume":"72","author":[{"given":"Anna Katharina","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Thoene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bietenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thalgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Secci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Ruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.07.024_bib0145","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2017.07.024_bib0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment","volume":"65","author":"Sridhar","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0155","doi-asserted-by":"crossref","first-page":"T179","DOI":"10.1530\/ERC-16-0422","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence","volume":"23","author":"Coutinho","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eururo.2017.07.024_bib0160","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.07.024_bib0165","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.07.024_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.07.024_bib0180","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.07.024_bib0185","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/14656566.2015.1055249","article-title":"Androgen pathway resistance in prostate cancer and therapeutic implications","volume":"16","author":"Maughan","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2017.07.024_bib0190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2017.07.024_bib0195","first-page":"12035","article-title":"Detecting predictive androgen receptor modifications in circulating prostate cancer cells","volume":"6","author":"Steinestel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.07.024_bib0200","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"71","author":"Scher","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0205","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.juro.2016.06.095","article-title":"A whole blood assay for AR-V7 and ARv567es in prostate cancer patients","volume":"196","author":"Liu","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.juro.2016.06.094","article-title":"AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate","volume":"197","author":"Todenh\u00f6fer","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","article-title":"Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer","volume":"23","author":"Qu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.07.024_bib0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2017.07.024_bib0225","doi-asserted-by":"crossref","first-page":"16613","DOI":"10.1200\/JCO.2016.34.15_suppl.e16613","article-title":"Detection of AR-V7 using cell-free RNA (cfRNA) in prostate cancer","volume":"34","author":"Usher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0230","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/ijms17081308","article-title":"The significance of epithelial-to-mesenchymal transition for circulating tumor cells","volume":"17","author":"K\u00f6lbl","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2017.07.024_bib0235","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working *Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.07.024_bib0245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","article-title":"REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"100","author":"McShane","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.eururo.2017.07.024_bib0250","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","article-title":"The Digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2017.07.024_bib0255","first-page":"21","article-title":"Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer","volume":"8","author":"Takeuchi","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0260","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0265","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","article-title":"Serial blood-based analysis of AR-V7 in men with advanced prostate cancer","volume":"26","author":"Nakazawa","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0270","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","article-title":"Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells","volume":"68","author":"Onstenk","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2016.07.021","article-title":"Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer","volume":"71","author":"Bernemann","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.07.024_bib0280","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acs.analchem.6b03980","article-title":"International interlaboratory digital PCR study demonstrating high reproducibility for the measurement of a rare sequence variant","volume":"89","author":"Whale","year":"2017","journal-title":"Anal Chem"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381730653X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381730653X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T12:02:00Z","timestamp":1570017720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381730653X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S030228381730653X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.07.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}